Titre :

Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Auteur(s) :

Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Labopin, Myriam [Auteur]
CHU Saint-Antoine [AP-HP]
Swoboda, Ryszard [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Kulagin, Alexander [Auteur]
Pavlov First Saint Petersburg State Medical University [St. Petersburg]
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Rovira, Montserrat [Auteur]

Blaise, Didier [Auteur]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Vydra, Jan [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Choi, Goda [Auteur]
University Medical Center Groningen [Groningen] [UMCG]
Reményi, Péter [Auteur]
Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet [Budapest, Hungary]
Koc, Yener [Auteur]
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Ciceri, Fabio [Auteur]
Ospedale San Raffaele
Mohty, Mohamad [Auteur]
CHU Saint-Antoine [AP-HP]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Date de publication :

2023-02-25

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Post-transplant cyclophosphamide (PTCy) is being increasingly used as graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia ...
Lire la suite >Post-transplant cyclophosphamide (PTCy) is being increasingly used as graft-versus-host disease (GVHD) prophylaxis post allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) transplanted in first complete remission (CR1). However, results may differ in patients transplanted in CR2. We retrospectively evaluated transplant outcomes of adult AML patients transplanted between 2010–2019 from 9–10/10 human leukocyte antigen (HLA)-matched unrelated donor (UD) in CR2. In total, 127 patients were included (median age 45.5 years, 54% male). Median follow-up was 19.2 months. Conditioning was myeloablative (MAC) in 50.4% and the graft source was peripheral blood in 93.7% of the transplants. Incidence of acute (a)GVHD II-IV and III-IV was 26.2% and 9.2%. Two-year total and extensive chronic (c)GVHD were 34.3% and 13.8 %, respectively. Two-year non-relapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS), and GVHD-free, relapse-free survival (GRFS) were 17.2%, 21.1%, 61.7, %, 65.2%, and 49.3%, respectively. Time from diagnosis to transplant (>18 months) was a favorable prognostic factor for RI, LFS, OS, and GRFS while favorable risk cytogenetics was a positive prognostic factor for OS. The patient’s age was a poor prognostic factor for NRM and cGVHD. Finally, the female-to-male combination and reduced intensity conditioning (RIC) were poor and favorable prognostic factors for cGVHD, respectively. We conclude that PTCy is an effective method for GVHD prophylaxis in AML patients undergoing allo-HCT in CR2 from UD.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-11T23:18:06Z
2024-03-04T14:23:45Z